Galapagos NV (GLPG)

Etorro trading 970x250
Galapagos NV (GLPG) Logo

About Galapagos NV

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company’s clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium. Address: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800

Galapagos NV News and around…

Latest news about Galapagos NV (GLPG) common stock and company :

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study
05 Oct, 2021 Yahoo! Finance

Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.

Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients
05 Oct, 2021 FinancialContent

Galapagos NV(NASDAQ: GLPG)announced results of two post-hoc analysesfrom the SELECTION and SELECTION LTE studies of ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
04 Oct, 2021 Yahoo! Finance

Continuing filgotinib 200mg among induction non-responders at week 10 resulted in clinical benefits for ulcerative colitis (UC) patients in the long-term extension study (LTE)Treatment with filgotinib 200mg resulted in clinically meaningful improvements in health-related quality of life (HRQoL) measures by week 58 among patients with UC Mechelen, Belgium; 4 October 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced results of two post-hoc analyses from the SELECTION and SELE

Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
04 Oct, 2021 FinancialContent

Galapagos NV(NASDAQ: GLPG) hasrandomized the last patient into the DIVERSITY Phase 3 studyof filgotinib in the ...

Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
04 Oct, 2021 Yahoo! Finance

1,374 patients enrolled into the phase 3 study across 369 global sitesTopline data anticipated in H1 2023Galapagos will assume responsibility for the DIVERSITY studyMechelen, Belgium; 4 October 2021, 07.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced randomization of the last patient into the multi-center, global DIVERSITY Phase 3 study. The study is designed to evaluate the efficacy and safety of filgotinib, a JAK1 preferential inhibitor, in the induction and maintenance of remis

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Galapagos increases share capital through subscription right exercises
20 Sep, 2021 FinancialContent
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
17 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's After-Market Session
31 Aug, 2021 FinancialContent

Gainers Sonnet BioTherapeutics (NASDAQ:SONN) stock moved upwards by 20.91% to $0.68 during Monday's after-market session. Today's ...

Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
31 Aug, 2021 FinancialContent

After 22 years at the helm ofGalapagos NV(NASDAQ: GLPG), chief executive Onno van de Stolpe hasdecided it is time ...

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
31 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Galapagos announces planned retirement of CEO
30 Aug, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
19 Aug, 2021 FinancialContent

Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ:PAYS) was changed from Neutral to Buy. In ...

Galapagos NV (GLPG) Q2 2021 Earnings Call Transcript
07 Aug, 2021 FinancialContent

GLPG earnings call for the period ending June 30, 2021.

Galapagos reports H1 financial results with refocused pipeline and operational progress
05 Aug, 2021 FinancialContent
Hedge Funds Are Buying Galapagos NV (GLPG)
21 Jul, 2021 Yahoo! Finance

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

54 Biggest Movers From Yesterday
16 Jul, 2021 FinancialContent

Gainers Sight Sciences, Inc. (NASDAQ: SGHT) shares jumped 39.6% to settle at $33.50 on Thursday as the company priced its IPO at ...

Here's Why Galapagos Stock Is Falling Today
15 Jul, 2021 FinancialContent

The company's new salt-inducable kinase inhibitor program is getting off to a rocky start.

32 Stocks Moving In Thursday's Mid-Day Session
15 Jul, 2021 FinancialContent

Gainers ATA Creativity Global (NASDAQ: AACG) shares jumped 37.8% to $4.1050. Verb Technology Company, Inc. (NASDAQ: VERB) shares ...

Galapagos (GLPG) Falls on Inflammatory Study Data Readout
15 Jul, 2021 Yahoo! Finance

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Galapagos NV (GLPG) is a NASDAQ Common Stock listed in , ,

970x250